Here's a clear, structured summary of NeOnc Technologies' SEC filing (Form 424B5):

🧾 What This Document Is

This is a Prospectus Supplement for a $75,000,000 "at-the-market" (ATM) offering of NeOnc's common stock. It updates and adds details to a base prospectus filed earlier. NeOnc can sell shares gradually, at market prices, through placement agents BTIG, LLC and A.G.P./Alliance Global Partners.

🏢 What The Company Does

👉 In simple terms: NeOnc is a clinical-stage biopharmaceutical company developing treatments for aggressive brain cancers (like glioblastoma and metastatic tumors). Their core challenge is the blood-brain barrier, which blocks most drugs from reaching the brain. They focus on novel delivery methods (like intranasal sprays) to bypass this barrier.

• Lead Products:
  • NEO100: Purified perillyl alcohol (POH) delivered intranasally. Currently in Phase IIa trials for recurrent malignant gliomas (brain cancers) and skull-based meningiomas. Also being studied as a delivery vehicle (e.g., with levodopa for Parkinson's).
  • NEO212: A combination of temozolomide (chemo) and perillyl alcohol. Phase I/II trial (oral delivery) started in late 2023 for primary and secondary brain tumors.
• Status: No products are approved or sold yet. They have no sales/marketing infrastructure.

💰 Financial Reality Check

• Revenue: Almost none. Generated only $122,990 total from Jan 2023 to Dec 2025. Expects minimal revenue "for the foreseeable future."
• Losses: Significant. Net loss of $62.1 million (2025) and $11.9 million (2024). Accumulated deficit: $112.8 million.
• Cash Burn: Heavily reliant on fundraising to operate and fund trials.
• Tax Liability: Owes approx. $7.0 million in unpaid federal/state withholding taxes related to employee stock grants (penalties/interest accruing).

🚀 The Offering & Use of Proceeds

• Goal: Raise up to $75 million gross by selling shares incrementally at market price.
• Costs: Placement Agents get a 3% commission on gross proceeds.
• Use of Proceeds:
  1. $7.0 million: Pay the overdue tax liabilities mentioned above.
  2. Fund further clinical trials for their drug candidates (NEO100, NEO212).
  3. Working capital & general corporate purposes.
• Dilution Warning: Investing means immediate dilution. Based on Dec 31, 2025, data:
  • Net tangible book value was negative $(0.88) per share.
  • At the assumed offering price ($5.37), new investors face immediate dilution of $3.89 per share (72%).

📦 Financial Position & Key Risks

• Weak Balance Sheet: Negative net tangible book value, significant losses, no revenue, large accumulated deficit.
• Major Risks Highlighted:
  • High Burn Rate: Needs this cash to survive and fund trials.
  • Clinical Trial Risk: Success is uncertain; failure would be devastating.
  • Regulatory Risk: FDA approval is required but not guaranteed.
  • Dilution: Further dilution likely from warrant exercises, future offerings.
  • Management Discretion: Broad leeway on how to use the funds.
  • IP Risk (Bayh-Dole): Government may have rights to some IP developed with funding, including "march-in" rights and US manufacturing preference.
  • Tax Liability Risk: Failure to pay the $7M tax bill could lead to penalties and collection actions.

🔮 What's Next

• Continue running Phase II trials for NEO100 (expect data readout potentially by end of 2026).
• Progress NEO212 Phase I/II trial.
• Use ATM offering proceeds to fund these activities and pay the tax bill.
• Seek future partnerships or funding as needed.

⚖️ Big Picture

• 👍 Strengths: Focused on critical unmet need (brain tumors), innovative delivery approaches, active clinical trials.
• ⚠️ Critical Risks: Pre-revenue biotech with severe cash burn, significant losses, major dilution, reliance on this offering to pay bills and fund trials, high scientific/regulatory risk. The offering is a lifeline, not growth capital.

🧠 The Analogy

Imagine NeOnc is a team building a revolutionary bridge (their drugs) over a massive, impassable canyon (the blood-brain barrier). They have promising blueprints (preclinical data) and are building test sections (clinical trials), but they've run out of materials and money. This offering is like selling shares in the bridge-building company right now to pay off overdue lumber bills (the $7M tax liability) and buy more materials to keep building. Investors are betting the bridge will eventually be completed and valuable, but right now, they're funding the construction costs and facing massive dilution for the privilege.

🧩 Final Takeaway

NeOnc is raising up to $75 million primarily to pay urgent tax debts and fund ongoing clinical trials for its unapproved brain cancer drugs. Investors face immediate, severe dilution and bet on high-risk, long-term scientific success while the company burns cash with no revenue. This offering is essential for NeOnc's near-term survival.